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Summary
Background: Screening HIV-positive patients for proteinuria would result in early recognition of
HIV-associated nephropathy (HIVAN). This would allow diagnosis and treatment of HIVAN at an
early stage and hence prevent further disease progression. This study was undertaken to
determine the frequency of proteinuria and its associated factors in Iranian HIV-positive patients.
Methods: In this study, 171 HIV-positive patients were screened for proteinuria. Proteinuria was
defined as 1+ protein on the urine dipstick. A questionnaire was used to collect patient
sociodemographic and clinical data. Hepatitis B surface antigen (HBsAg), hepatitis C antibody
(anti-HCV), serum albumin, and creatinine were tested in all patients. CD4 counts were obtained
by flow cytometry.
Results: Out of 171 HIV-positive patients, 21 (12.3%) had proteinuria. There were no significant
differences between patients with and without proteinuria with regard to age, sex, risk behaviors
for HIV acquisition, stage of infection, concurrent antiretroviral therapy, systolic and diastolic
blood pressure, serum albumin and creatinine, glomerular filtration rate (GFR), and presence of
anti-HCVor HBsAg. Patients with proteinuria had a lower CD4 count and creatinine clearance than
those without proteinuria.* Corresponding author. Tel.: +98 21 66465147; fax: +98 21 66409467.
E-mail address: araghakhani@hotmail.com (A. Aghakhani).
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Conclusion: Proteinuria was relatively high in Iranian HIV-positive patients. The group at higher
risk was that of patients with lower CD4 counts and creatinine clearance.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
Currently the total number of people living with HIV in the
Middle East and North Africa is 540 000. Approximately
92 000 individuals were newly infected in 2004 and 28 000
people died of AIDS during the same time period. With the
increasing spread of sexually transmitted infections (STIs),
injection drug users (IDUs), numbers of unemployed youths, a
conservative culture, and low awareness of HIV, the region is
especially vulnerable to a large-scale epidemic.1
A significant prevalence of renal disease exists in the HIV
seropositive outpatient population.2 The renal disorders in HIV
infection can be broken down into three large groups including
HIV-specific glomerulopathy, acute renal failure syndromes,
and fluid/electrolytes and acid—base disorders of HIV.3
Classic HIV-associated nephropathy (HIVAN) is character-
ized by nephrotic range proteinuria, renal dysfunction, and
rapidlyprogressing renal insufficiency (before the introduction
of highly active antiretroviral therapy (HAART), themean time
from presentation to the onset of end-stage renal disease
(ESRD) was less than 6 months). Eighty-eight percent of cases
are in blacks in the 20—64 years age group. Hematuria, gross or
microscopic, although described, is not a classic feature.
Patients are often normotensive and normovolemic.3
While an understanding of the epidemiology and clinical
course of HIVAN is growing, little is known about the risk
factors and clinical course of the other renal diseases that
may also occur as a complication of HIV infection.4 HIVAN can
be an initial presentation of HIV infection; however, HIV is
usually advanced when the diagnosis is made. Winston et al.
studied 20 seropositive, predominantly African American
patients presenting with proteinuria and azotemia. They
found that the mean CD4 count was 60/mm3; none of the
patients had a CD4 count greater than 200/mm3. They also
reviewed six studies reporting CD4 counts in patients with a
diagnosis of HIVAN, and found that the majority of patients
had CD4 counts less than 200/mm3.5 Many reports suggest
that black race,6—13 Haitian background,14 male gender,8
injection drug use,6—14 and a decreased CD4 cell count15
are risk factors for the development of HIVAN.
Microalbuminuria may be an early marker of HIVAN, and
screening for its presence may be beneficial. Renal biopsy
may be considered in seropositive patients who present with
persistent microalbuminuria, especially with low CD4 counts
irrespective of good renal function. This will allow diagnosis
and treatment of HIVAN at an early stage and may prevent
further disease progression.16
Screening HIV patients for proteinuria would result in
early recognition of HIVAN or precursor lesions. Therefore,
screening asymptomatic patients for proteinuria and early
intervention with angiotensin-converting enzyme (ACE) inhi-
bitors and HAART should be considered.3 However, there are
no HIV/AIDS epidemiological data available specific for the
Middle East, and surveys conducted in a large area includingthe Middle East are lacking.1 This study was undertaken to
determine the frequency of proteinuria and its associated
factors in Iranian HIV-positive patients.
Patients and methods
In this cross-sectional study, 171 HIV-positive patients
referred to the behavioral disease consulting center in Teh-
ran, Iran from December 2005 through December 2006, were
screened for proteinuria. The study enrolled patients with
HIV infection tested with two enzyme-linked immunosorbent
assays (ELISA) and confirmed with Western blot.
Proteinuria measurement was done in the absence of
pregnancy, menstruation, fever, or urinary tract infection.
Informed consents were obtained from all subjects. A ques-
tionnaire was used to collect sociodemographic data, med-
ical history, nephrotoxic and antihypertensive drugs
consumption, antiretroviral medication, stage of the infec-
tion (HIV/AIDS), and high-risk behaviors for HIV acquisition. A
physician checked systolic and diastolic blood pressures.
All patients were also tested for hepatitis B surface anti-
gen (HBsAg) and hepatitis C antibody (anti-HCV) by ELISA.
The commercial HBsAg and anti-HCV enzyme immunoassay
kits were from Hepanosticka Biomerieux, The Netherlands
and Biorad, Italy, respectively. A recombinant immunoblot
assay (RIBA Innogenetics, Ghent, Belgium) was employed to
confirm anti-HCV reactivity.
In all patients CD4 lymphocyte counts were done by flow
cytometry and defined as cells/mm3. Serum albumin and
creatinine were also tested in all patients. Estimated crea-
tinine clearance and glomerular filtration rate (GFR) were
calculated using the Cockcroft—Gault equation17 and simpli-
fied MDRD (Modification of Diet in Renal Disease study),18
respectively.
Proteinuria was defined as 1+ protein on the urine dip-
stick. Antiretroviral medication was coded as: (1) none, (2)
antiretroviral medications from nucleoside reverse transcrip-
tase inhibitors (NRTI), and (3) combination therapy (more
than one antiretroviral agent including at least one PI (pro-
tease inhibitor). None of our subjects had received nephro-
toxic antiretroviral medications like indinavir and tenofovir.
Statistical analysis
Chi-square and t2 tests were used with the SPSS 11.5 program
for statistical analysis. Data are presented as means  stan-
standard deviations or, when indicated, as absolute number
andpercentage. Ap value of<0.05was considered significant.
Results
A total of 171 HIV-positive patients were enrolled in our
study; 80.7% of them were male and 19.3% were female with
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Table 1 Demographic and clinical characteristics of HIV-positive patients based on the presence and absence of proteinuria (total
N = 171)
Proteinuria p-Value
Present Absent
Number (%) 21 (12.3%) 150 (87.7%) -
Age (years) 35.68  9.59 37.17  9.12 NS
Sex (M/F) 17/4 121/29 NS
Stage of infection (HIV/AIDS) 12/9 77/73 NS
Albumin (g/dl) 4.39  0.55 4.65  0.57 NS
Creatinine (mg/dl) 0.99  0.2 0.92  0.19 NS
Estimated creatinine clearance (ml/min) 84.9  30.6 102.4  28.8 <0.05
Estimated GFR (ml/min/1.73 m2) 86.8  26.26 99  27.7 NS
Absolute CD4 lymphocyte count (cells/mm3) 336.66  196.40 494.90  223.26 <0.05
HBsAg (+) 2 (9.5%) 10 (6.7%) NS
Anti-HCV (+) 9 (42.9%) 81 (54%) NS
Systolic blood pressure (mmHg) 113.95  17.99 113.39  13.74 NS
Diastolic blood pressure (mmHg) 71.58  12.69 71.64  8.94 NS
Antiretroviral medication NS
None 13 (61.9 %) 91 (60.7 %)
Nucleoside reverse transcriptase inhibitor 0 (0%) 7 (4.7%)
Combination therapy 8 (38.1%) 52 (34.7%)
Risk behavior for HIV acquisition NS
Intravenous drug use 15 (71.4%) 102 (68%)
Heterosexual 3 (14.3%) 30 (20%)
Homosexual 0 (0%) 1 (0.7%)
Transfusion 1 (4.8%) 6 (4%)
Not identified 2 (9.5%) 11 (7.3%)
Values are mean  SD or n (%). NS, not significant; GFR, glomerular filtration rate; HBsAg, hepatitis B surface antigen; anti-HCV, hepatitis C
antibody.a mean age 37  9.16 years. None of them had a history of
diseases that affect renal function such as diabetes mellitus.
Also none of them had consumed nephrotoxic and/or anti-
hypertensive drugs. Of the patients, 52% were HIV-infected
and 48% had clinical AIDS. Their mean systolic blood pressure
(SBP) was 113.46  14.25 and mean diastolic blood pressure
(DBP) was 71.64  9.42. One hundred and four patients
(60.8%) had received no antiretroviral medication; 4.1%
and 35.1% had received NRTI and combination therapy,
respectively. Their serum albumin ranged between 2.50
and 5.80 g/dl (mean 4.6  0.6) and serum creatinine ranged
between 0.4 and 1.8 mg/dl (mean 0.92  0.2). The CD4
lymphocytes were between 30 and 985.4 cell/mm3 (mean
388.5  220.7). HBsAg and anti-HCV were positive in 7.0%
and 52.6% of patients, respectively. Of the patients, 68.4%
were IDUs, 19.3% heterosexual, 0.6% homosexual, and 4.1%
had received infected blood and blood products; for 7.6% the
means of HIV acquisition was not identified.
Proteinuria was detected in12.3% (n = 21; 95% CI 7.1—
16.9) of the patients using the urine dipstick. Demographic
and clinical characteristics of patients with and without
proteinuria are summarized in Table 1.
There were no significant differences between patients
with and without proteinuria with regard to age, sex, risk
behaviors for HIV acquisition, stage of the infection, con-
current antiretroviral therapy, systolic and diastolic blood
pressure, serum albumin and creatinine, GFR, and presence
of anti-HCVor HBsAg. However, patients with proteinuria hada lower CD4 count (336.66  196.40 vs. 494.90  223.26
cells/mm3, p < 0.05) and creatinine clearance (84.9  30.6
vs. 102.4  28.8 ml/min, p < 0.05) than those without pro-
teinuria.
Discussion
This study examined the frequency and associated factors
of proteinuria among Iranian HIV-positive patients. Protei-
nuria was present in 12.3% of the patients. It was asso-
ciated with lower CD4 counts and creatinine clearance, but
was not related to age, sex, risk behaviors for HIV acquisi-
tion, stage of the infection, concurrent antiretroviral
therapy, systolic and diastolic blood pressure, serum albu-
min and creatinine, GFR, and the presence of anti-HCV or
HBsAg. This relatively high prevalence of proteinuria shows
that renal disorders are prevalent in HIV-positive patients.
Because we did not perform renal biopsy, it is not possible
to determine whether proteinuric subjects had HIVAN or
some other type of nephropathy. A study by Ghahramani
et al. showed significant proteinuria (>1 g/dl) among 4.4%,
and proteinuria of >150 mg/dl among 33.1% of Iranian
kidney donors.19 However, the explanation of these find-
ings needs further study with more sensitive methods, in
different Iranian groups. We used a single measurement
method for proteinuria (urine dipstick), and hence the
prevalence of proteinuria could change in the study cohort
if a different method were used.
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including acute renal failure. Chronic renal failure directly
linked to HIV infection includes thrombotic microangio-
pathic renal diseases, immune-mediated glomerulonephri-
tides, and HIVAN. The most common cause of chronic renal
failure in HIV-1 seropositive patients is HIVAN. It is known
that the screening of all HIV-infected patients for protei-
nuria would result in early recognition of HIVAN or a pre-
cursor lesion.2
Hailemariam et al. showed clinical signs of nephropathy in
36% of HIV-infected patients, including proteinuria (18%),
abnormal urinary sediment (19.5%), and renal insufficiency
(11%).20 Gardner et al. reported that of 64 HIV-positive
women with renal abnormalities, 46 had proteinuria and
32 had high serum creatinine. HIV-infected women with renal
abnormalities did not differ from those without renal
abnormalities with regard to percentage using antiretroviral
therapy, mean log viral load, or mean CD4 cell count.21
Atta et al. showed that patients with HIVAN had signifi-
cantly higher creatinine and lower CD4 counts at the time of
biopsy than those without HIVAN. Injection drug use, pre-
sence of hepatitis C, and hypertension were not associated
with HIVAN.22 Crowley et al. showed that 14% of HIV-infected
patients had >1+ persistent proteinuria. The average CD4
count in the proteinuria group was 180 vs. 280 in the group
without proteinuria.23 Szczech et al. reported that in HIV-
positive women, the prevalence of asymptomatic proteinuria
was 32%. Predictors of proteinuria included increasing viral
load, black race, CD4 count <200/mm3, and presence of
hepatitis C. HBsAg positivity and serum creatinine levels
were not significantly different between patients with and
without proteinuria.24
Some reports have suggested that injection drug use8—11
may be a risk factor for HIVAN, but this likely represents
confounding with other epidemiologic factors from the early
stages of the HIVepidemic.25 Although male sex has also been
reported as a risk factor,8 the incidence of HIVAN in black
women is increasing proportionately to the escalating rate of
HIV infection in this group26,27 strongly suggesting that HIVAN
is not sex-specific.25 A large series of patients with HIVAN
confirmed that sex, risk factors for HIV acquisition, and CD4+
lymphocyte count at the time of diagnosis are not as sig-
nificant as previously described.28
These conflicting results may be related to various
factors such as the HIV infection rate in the general
population, the size of the study group, and the demo-
graphic and clinical features of the patients. As mentioned
before, data on the incidence and prognostic significance
of renal dysfunction in HIV disease are limited,21 and there
were no HIV/AIDS epidemiological data available specific
for the Middle East, especially regarding renal complica-
tions of HIV infection.1 So our study could define some
epidemiological aspects of renal disorders in HIV-positive
patients in this important area. Our findings support the
hypotheses regarding the need for better monitoring and
more aggressive treatment of HIV-infected patients with
lower CD4 counts.29
In conclusion, proteinuria was relatively high in Iranian
HIV-positive patients. The group at higher risk was that of
patients with lower CD4 counts and creatinine clearance. A
greater understanding of the risk factors and clinical mod-
ifying factors for HIV-related renal diseases is essential.Acknowledgment
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